Vizgen vs Cradle
Side-by-side comparison of AI visibility scores, market position, and capabilities
Vizgen is a Cambridge MA life sciences company commercializing MERSCOPE, a spatial genomics platform based on MERFISH technology licensed from Harvard; enables single-cell, subcellular-resolution RNA imaging in intact tissue;
About
Vizgen is a life sciences company founded in 2019 and headquartered in Cambridge, Massachusetts, that has commercialized the MERSCOPE platform — a spatial genomics instrument based on MERFISH (Multiplexed Error-Robust Fluorescence In Situ Hybridization) technology originally developed in the lab of Xiaowei Zhuang at Harvard University. MERSCOPE enables researchers to simultaneously measure the expression of hundreds to thousands of genes in individual cells while preserving the spatial location of those cells within intact tissue samples. This combination of single-cell resolution and spatial context is a significant advance over traditional bulk RNA sequencing (which loses spatial information) and earlier single-cell sequencing methods (which require tissue dissociation that destroys spatial architecture).
AI protein design platform combining language models with lab automation; active learning cycles for enzyme, antibody, and therapeutic protein engineering optimization.
About
Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, activity, and manufacturability. Founded in 2021 and headquartered in Amsterdam with teams in San Francisco, Cradle raised approximately $24 million and targets biopharmaceutical, agricultural, and industrial biotechnology companies that need to engineer proteins with specific functional properties.
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.